Clinical trials: Alopecia, Androgenetic
Androgenetic Alopecia, Hair Loss
Low Level Light Device as a Primary Therapy for Androgenetic Alopecia
The purpose of this research is to study the safety and effectiveness of a light therapy device for human hair growth. This device, called the GENIX, is a type of cold, or non-heat producing light emitting diode (LED) that will…
- Conditions
- Androgenetic Alopecia, Hair Loss, Thinning Hair, Balding
- Trial name
- NCT04558242
- Testing
- Genix
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Kiierr International, LLC
Hair Loss, Hair Loss/Baldness
HairDx Analytical Validation Study
The HairDx Test reports genetic variants associated with the development of FPHL.
- Conditions
- Hair Loss, Hair Loss/Baldness, Female Pattern Baldness, Androgenetic Alopecia
- Trial name
- NCT04379583
- Testing
- HairDx Sample Collection Kit
- Where
- United States
- Sponsor
- Applied Biology, Inc.
Androgenic Alopecia
Keravive by Hydrafacial for Scalp Health and Enhanced Hair Quality
The study aims to assess the efficacy and safety of Keravive by Hydrafacial treatments and Keravive Peptide Spray for scalp health and enhancing hair quality in patients with androgenic alopecia.
- Trial name
- NCT06112782
- Testing
- Keravive by Hydrafacial Treatments
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- Beauty Health
Androgenetic Alopecia
Plasma Rich in Growth Factors (PRGF-Endoret)in the Treatment of Androgenetic Alopecia
Androgenetic alopecia (AGA) or common baldness is the most common cause of hair loss in both men and women and is caused by the action of androgens in genetically predisposed individuals.
- Trial name
- NCT01885676
- Testing
- PRGF-Endoret, Saline Solution
- Where
- 2 sites in Spain
- Sponsor
- Biotechnology Institute IMASD
Androgenetic Alopecia
Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA
The study is a two part study, designed to validate safety results from the Phase 1 PP405-001 trial while also characterizing longer term safety and PK.
- Trial name
- NCT06393452
- Testing
- PP405 0.05% Topical Gel, Topical Vehicle Gel
- Where
- 8 sites in United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Pelage Pharmaceuticals, Inc.
Alopecia
A Study To Assess The Efficacy And Safety Of Dutasteride 0.5mg Once Daily For 6 Months In The Treatment Of Male Subjects With Androgenetic Alopecia
The aim of this Phase III study is to compare the efficacy, safety and tolerability of dutasteride (0.5mg) with placebo for 6 months, in Korean male subjects with androgenetic alopecia in the vertex region, types IIIv, IV and V…
- Trial name
- NCT00441116
- Testing
- Dutasteride 0.5mg oral tablets
- Volunteers
- 153 people
- Sponsor
- GlaxoSmithKline
Androgenic Alopecia
Computer-Assisted Hair Implantation Using ARTAS System VS Manual Implantation Technique Hair Restoration Study
To investigate and compare the safety and effectiveness of the ARTAS™ System to manual hair follicle implantation method following a nine month period of post-procedure evaluation.
- Trial name
- NCT02914587
- Testing
- ARTAS System, Manual Implantation
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Restoration Robotics, Inc.
Androgenetic Alopecia, Male Pattern Baldness
A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004512)
The purpose of the study is to evaluate the ability of injections of Ji Gami(TM) or Ji Gami(TM) DO in combination with minoxidil to induce hair growth in male and female subjects with hair loss.
- Conditions
- Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
- Trial name
- NCT01451125
- Testing
- Autologous cultured dermal and epidermal cells
- Where
- 4 sites in United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Aderans Research Institute
Androgenetic Alopecia
A Phase 2 Study to Evaluate the Safety and Efficacy of CKD-498 in Female Patients With Androgenetic Alopecia
This is a multi-centers, randomized, double-blind, parallel-group, Phase 2 Trial to evaluate the efficacy and safety of CKD-498 in female patients with Androgenetic Alopecia
- Trial name
- NCT05677438
- Testing
- CKD-498 dose#1, CKD-498 dose#2, CKD-498 dose#3
- Where
- South Korea
- Volunteers
- 121 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Androgenetic Alopecia
A Novel Approach to Treating Androgenetic Alopecia in Females With Low Level Laser Therapy
This study will acquire data on hair growth of the head that is the result of treatment with a non-heat generating, laser product.
- Trial name
- NCT01967277
- Testing
- Handi-Dome Laser, Incandescent red light source.
- Where
- 2 sites in United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Capillus, LLC
Androgenetic Alopecia, Male Pattern Baldness
A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0005995)
Evaluate the ability of injections of Ji Gami(TM) CN to induce hair growth in male and female subjects with hair loss.
- Conditions
- Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
- Trial name
- NCT01451190
- Testing
- Autologous cultured dermal and epidermal cells
- Where
- 9 sites in United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Aderans Research Institute
Androgenic Alopecia
Hair Growth Efficacy and Safety of NGF-574H in Adult With Androgenic Alopecia
The purpose of this study is to assess whether cosmetic investigational product containing NGF-574H is safe and effective in the treatment of androgenic alopecia in asian adults.
- Trial name
- NCT03676400
- Testing
- conditioned media of umbilical cord blood-derived stem cells
- Where
- South Korea
- Volunteers
- 84 people
- Sponsor
- Medipost Co Ltd.
Androgenic Alopecia
Effect of Pumpkin Seed Oil on Hair Growth in Men With Androgenetic Alopecia
Androgenic alopecia is the most common cause of hair loss in men. Finasteride and minoxidil are available in treatment of androgenetic alopecia, although the former causes decreased libido or ejaculate volume, erectile…
- Trial name
- NCT01852487
- Testing
- 400mg /day during 6 months
- Where
- South Korea
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Dream Plus
Androgenetic Alopecia
Dose-Ranging Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss
The purpose of this study is to evaluate the safety and efficacy of three doses of topical NEOSH101 applied once-daily (qd) for 16 weeks in men with thinning hair in the top and center of the scalp (Norwood/Hamilton grades III-IV…
- Trial name
- NCT00471510
- Testing
- tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
- Where
- Germany
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Neosil, Inc.
Androgenetic Alopecia, AGA
Safety and Efficacy of VDPHL01 in Males With AGA
This study will evaluate the safety and efficacy of VDPHL01 in male subjects with Androgenetic Alopecia (AGA). AGA (or male pattern baldness) is a genetic disorder caused by an excessive (too much) hair follicle response to…
- Conditions
- Androgenetic Alopecia, AGA, Male Pattern Baldness
- Trial name
- NCT06972264
- Testing
- VDPHL01
- Where
- 44 sites in United States
- Volunteers
- 480 people
- Sponsor
- Veradermics, Inc.
Androgenetic Alopecia
Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss
The purpose of this study is to measure the hair growth response to topical NEOSH101 when applied twice daily to the balding scalp for 16 weeks.
- Trial name
- NCT00418730
- Testing
- tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
- Where
- Germany
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Neosil, Inc.
Androgenetic Alopecia
A Study to Evaluate the Efficacy and Safety of AD-208
The purpose of this study is to evaluate the efficacy and safety of AD-208.
- Trial name
- NCT04825561
- Testing
- AD-208, AD-2081
- Where
- South Korea
- Volunteers
- 139 people
- Sponsor
- Addpharma Inc.
Alopecia, Alopecia, Androgenetic
Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia
This study will investigate the safety, tolerability, and pharmacokinetics of new formulation of bimatoprost following topical application in patients with alopecia.
- Conditions
- Alopecia, Alopecia, Androgenetic, Baldness
- Trial name
- NCT01189279
- Testing
- bimatoprost Formulation A, bimatoprost Formulation B, bimatoprost Formulation C
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Allergan
Alopecia
To Evaluate Safety and Efficacy of KX-826 in Chinese Female Subjects With Androgenetic Alopecia
This was a multi-center, randomized, double-blind, placebo-controlled Phase II clinical study of KX-826 Tincture in Chinese adult female subjects with AGA.
- Trial name
- NCT06409650
- Testing
- KX-826 dosed at 2.5mg, KX-826 dosed at 5 mg
- Where
- 15 sites in China
- Volunteers
- 160 people
- Sponsor
- Suzhou Koshine Biomedica, Inc.
Androgenetic Alopecia, Male Pattern Baldness
A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0006931)
Evaluate the ability of injections of Ji Gami(TM) CN to induce hair growth in male and female subjects with hair loss.
- Conditions
- Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
- Trial name
- NCT01669746
- Testing
- Autologous cultured mixed population of dermal cells
- Where
- 7 sites in United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Aderans Research Institute